Insider Selling: Cryolife VP Sells 10,000 Shares of Stock (CRY)
Cryolife (NYSE:CRY) VP Bruce G. Anderson unloaded 10,000 shares of Cryolife stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $10.52, for a total transaction of $105,200.00. Following the sale, the vice president now directly owns 34,564 shares of the company’s stock, valued at approximately $363,613. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Cryolife (NYSE:CRY) traded down 1.15% on Thursday, hitting $10.35. 29,069 shares of the company’s stock traded hands. Cryolife has a 52-week low of $6.01 and a 52-week high of $12.14. The stock has a 50-day moving average of $9.64 and a 200-day moving average of $9.48. The company has a market cap of $289.0 million and a P/E ratio of 19.53.
Cryolife (NYSE:CRY) last released its earnings data on Thursday, July 24th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.03. The company had revenue of $34.69 million for the quarter, compared to the consensus estimate of $35.72 million. During the same quarter in the previous year, the company posted $0.08 earnings per share. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. Analysts expect that Cryolife will post $0.20 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, September 19th. Stockholders of record on Friday, September 12th will be given a dividend of $0.03 per share. This represents a $0.12 dividend on an annualized basis and a yield of 1.15%. The ex-dividend date of this dividend is Wednesday, September 10th.
CryoLife, Inc (NYSE:CRY) is a biological medical device company.
Receive News & Ratings for Cryolife Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.